title: [Cutaneous pseudolymphoma with two types of anti-TNFα: a class effect?].
authors.affiliation: Service de dermatologie, hôpital Brabois, bâtiment P.-Canton, rue du Morvan, 54511 Vandœuvre-lès-Nancy cedex, France. jl.schmutz@chu-nancy.fr
authors.forename: J-L
authors.initials: JL
authors.lastname: Schmutz
authors.forename: P
authors.initials: P
authors.lastname: Trechot
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000276:immunology; D015897:Comorbidity; D003875:Drug Eruptions / Q000175:diagnosis* / Q000276:immunology; D057915:Drug Substitution; D005260:Female; D006801:Humans; D000069285:Infliximab; D019310:Pseudolymphoma / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D012008:Recurrence; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab